Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Wellington Management and related entities report beneficial ownership of 5,318,624 shares of Immatics N.V. common stock, representing approximately 4.38% of the class. The filing discloses no sole voting or dispositive power; voting is held as shared voting power of 4,545,848 shares and shared dispositive power of 5,318,624 shares. These shares are owned of record by clients of Wellington investment advisers.
The statement clarifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control; no client is identified as having the right to dividends or sale proceeds for more than 5% of the class.